How Daiichi Sankyo Is Navigating Patent Cliffs, M&A, and Value‑Based Pricing to Sustain Growth
Explore how Daiichi Sankyo’s patent‑cliff strategy, M&A moves, and value‑based pricing shape its future growth and investor appeal.
4 minutes to read
Lisa Martinez
Pharma Business Analyst
Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.
AI Author, more information here
Alnylam Boosts Shareholder Value: Buy‑Back, $508 Target, & Nasdaq 100 Debut Drive Growth in Non‑Opioid Therapeutics
Alnylam’s Nasdaq 100 debut, $508 price target, and strategic debt buy‑back signal a stronger capital structure poised to accelerate its RNAi pipeline and dominate the growing non‑opioid therapeutics market.
5 minutes to read
Investors Eye AstraZeneca: Ovarian‑Cancer Pipeline, Patent Cliffs and M&A Drive Growth
Discover why AstraZeneca’s ovarian‑cancer phase‑three study and strategic market‑access plan could boost its $26 billion revenue forecast and 12 % IRR—read the latest analyst insights and M&A prospects.
4 minutes to read
Fosun Pharma Sees Rapid Growth: China’s Breakthrough Drug, Pfizer Deal & Strong Market Potential
Shanghai Fosun Pharmaceutical’s new drug approval and Pfizer partnership put it in line for early market entry, patent‑cliff protection, and strong global revenue potential.
- Shanghai Fosun Pharmaceutical Group Co Ltd
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read
Grifols Faces Investor Split as Market Access, Patent Cliffs Shake Up Plasma Business
Grifols SA’s split analyst outlook: a major bank cuts its target while a sovereign wealth fund ups its stake—find out how plasma‑derived drug pressures, R&D bets and diagnostics growth could shape its future.
4 minutes to read
IQVIA Cuts Debt & Interest, Boosts Balance Sheet Amid Belgian Regulator Scrutiny
IQVIA refines debt, cuts interest, and faces Belgian regulatory probe—boosting margins and market‑access plans while navigating competition scrutiny.
4 minutes to read
Kyowa Kirin’s KOMZIFTI Shows Strong AML Response, Boosting Market & Patent Outlook
Kyowa Kirin’s new data on KOMZIFTI shows a 60 %+ complete‑response rate in AML, boosting value‑based pricing and market access prospects before generics erode the niche.
3 minutes to read
Genmab’s Epcoritamab Breakthrough: $1.1 B US NPV, Market & M&A Outlook
Genmab’s epcoritamab shows 70‑80% response in follicular lymphoma, with a US NPV of $1.1 B—boosting its value, pricing strategy, and M&A appeal.
5 minutes to read
Takeda’s Rusfertide Phase‑3 Results Show Durable Safety, Powering PV Market Access & Growth
Takeda’s 52‑week VERIFY study shows rusfertide safely reduces phlebotomy in polycythemia vera, offering durable efficacy and a strong commercial case for market access.
- Takeda Pharmaceutical Co Ltd
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
5 minutes to read
Incyte’s Breakthrough Designation Paves Way for High‑Value CALR‑Targeted Therapy
Incyte’s Breakthrough Therapy and Fast‑Track designations for INCA033989 unlock a $2‑$3 billion market, offering a novel calreticulin‑targeting antibody that could reshape myeloproliferative neoplasm treatment and boost shareholder value.
4 minutes to read